The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
CTEP #8342 autophagy modulation with antiangiogenic therapy: A phase I trial of sunitinib (Su) and hydroxychloroquine (HCQ).
Nataliya Melnyk
No relevant relationships to disclose
Xiaoqi Xie
No relevant relationships to disclose
Danny Ju Yong Koh
No relevant relationships to disclose
Megha Rajpal
No relevant relationships to disclose
Rebecca Anne Moss
No relevant relationships to disclose
Darlene Gibbon
No relevant relationships to disclose
James M. Cleary
No relevant relationships to disclose
Minh-Thu Tran
No relevant relationships to disclose
Pamela Scott
No relevant relationships to disclose
Mark N. Stein
No relevant relationships to disclose
Antoinette R. Tan
No relevant relationships to disclose
Shari Adams
No relevant relationships to disclose
Diana C. Lindquist
No relevant relationships to disclose
Pamela Jo Harris
No relevant relationships to disclose
Naoko Takebe
No relevant relationships to disclose
Hongxia Lin
No relevant relationships to disclose
Joseph Aisner
No relevant relationships to disclose
Eileen White
No relevant relationships to disclose
Robert S. DiPaola
No relevant relationships to disclose
Janice M. Mehnert
No relevant relationships to disclose